LB80317
LB80317 is an active metabolite of LB80380 and suppresses the DNA synthesis of HBV with an EC50 of 0.5 μM. LB80317 has antiviral effect and has the potential for chronic hepatitis B treatment.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 441785-24-6
- 分子式: C10H14N5O5P
- 分子量:315.22
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示
More
生物活性
EC50: 0.5 μM (DNA synthesis of HBV)[2]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | EC50 |
0.5 μM
Compound: 1
|
Compound tested for anti-HBV (hepatitis B virus) activity in HepG2 2.2.15 cell line
Compound tested for anti-HBV (hepatitis B virus) activity in HepG2 2.2.15 cell line
|
[PMID: 15139764] |
| HepG2 | CC50 |
>1000 μM
Compound: 1
|
Cytotoxic activity in HepG2 2.2.15 cell line
Cytotoxic activity in HepG2 2.2.15 cell line
|
[PMID: 15139764] |
After phosphorylation to di- and triphosphate forms, LB80317 is incorporated into the viral DNA inside the nucleocapsid, which inhibits further DNA synthesis. In in vitro studies using cell line models, the drug concentrations causing 50% reduction in HBV DNA produced (EC50) is 0.5 μM for LB80317[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 441785-24-6
-
分子量 315.22
-
分子式 C10H14N5O5P
-
SMILES
OP(O)(COC1(CN2C=NC3=C2N=C(N)NC3=O)CC1)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Man-Fung Yuen, et al. Pharmacokinetics of LB80331 and LB80317 Following Oral Administration of LB80380, a New Antiviral Agent for Chronic Hepatitis B (CHB), in Healthy Adult Subjects, CHB Patients, and Mice. Antimicrob Agents Chemother. 2009 May;53(5):177 [Content Brief]
[2]. Lung-Yi Mak, et al. Pharmacokinetic Evaluation of Besifovir for the Treatment of HBV Infection. Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):101-106. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
LB80317 関連分類
HY-106235 関連分類
Powered by Bioz